| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -7,1 k € | -113.3% | 53,3 k € | +700.0% | 6,7 k € | -95.8% | 157,0 k € | +1014.9% | 14,1 k € | +114.1% | 6,6 k € | -29.1% | 9,3 k € | -69.1% | 30,0 k € | -6.0% | 31,9 k € | -29.9% | 45,6 k € | |
| EBITDA | -7,6 k € | -139.2% | 19,3 k € | +321.5% | 4,6 k € | -96.8% | 144,9 k € | +1111.0% | 12,0 k € | +92.1% | 6,2 k € | -21.2% | 7,9 k € | -69.2% | 25,7 k € | -12.1% | 29,2 k € | -34.9% | 44,9 k € | |
| Operating profit | -7,6 k € | -139.2% | 19,3 k € | +321.5% | 4,6 k € | -96.8% | 144,9 k € | +1111.0% | 12,0 k € | +92.1% | 6,2 k € | -16.7% | 7,5 k € | -70.9% | 25,7 k € | -12.1% | 29,2 k € | -34.9% | 44,9 k € | |
| Profit/loss | -10,5 k € | +47.3% | -19,9 k € | -865.0% | -2,1 k € | -115.5% | 13,3 k € | +237.5% | 3,9 k € | +476.7% | -1,0 k € | -189.3% | 1,2 k € | -92.8% | 16,3 k € | +6.8% | 15,3 k € | -43.8% | 27,2 k € | |
| Equity | 63,6 k € | -14.1% | 74,1 k € | -21.1% | 94,0 k € | -2.1% | 96,0 k € | +16.0% | 82,8 k € | +5.0% | 78,9 k € | -1.3% | 79,9 k € | +1.5% | 78,7 k € | +26.1% | 62,4 k € | +32.4% | 47,2 k € | |
| Total assets | 151,0 k € | -9.1% | 166,2 k € | -52.8% | 352,3 k € | -34.9% | 541,1 k € | -14.7% | 634,5 k € | +170.4% | 234,7 k € | -3.4% | 242,9 k € | +46.3% | 166,1 k € | +31.4% | 126,3 k € | -39.4% | 208,4 k € | |
| Cash | 74,6 k € | -32.4% | 110,4 k € | -19.6% | 137,3 k € | +9.4% | 125,5 k € | -56.4% | 287,9 k € | +1038.9% | 25,3 k € | -65.7% | 73,7 k € | -31.6% | 107,7 k € | +189.4% | 37,2 k € | -10.5% | 41,6 k € | |
| Debts | 87,0 k € | +26.6% | 68,7 k € | -73.4% | 258,3 k € | -42.0% | 445,1 k € | -19.3% | 551,7 k € | +254.0% | 155,8 k € | -4.4% | 163,0 k € | +86.7% | 87,3 k € | +36.6% | 63,9 k € | -60.4% | 161,3 k € | |
Private limited company · Dison · incorporated on 03/11/2015
Private limited company loss-making in the latest fiscal year. Cash position declining (-32.4%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
IKRIS PHARMA INTERNATIONAL is a Private limited company incorporated in 2015. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Dison.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette